UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 85

Sortiert nach

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Annals of oncology, 2019-07, Vol.30 (7), p.1121-1126

2019

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

Annals of oncology, 2020-12, Vol.31 (12), p.1725-1733

2020

Link zum Volltext

Verfügbarkeit prüfen

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib

Lung cancer (Amsterdam, Netherlands), 2017-09, Vol.111, p.84-87

2017

Link zum Volltext

Verfügbarkeit prüfen

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Annals of oncology, 2020-08, Vol.31 (8), p.1056-1064

2020

Link zum Volltext

Verfügbarkeit prüfen

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

Annals of oncology, 2016-10, Vol.27, p.vi328-vi328

2016

Link zum Volltext

Verfügbarkeit prüfen

Innovative personalized medicine in gastric cancer: time to move forward

Clinical genetics, 2014-07, Vol.86 (1), p.37-43

2014

Link zum Volltext

Verfügbarkeit prüfen

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

Annals of oncology, 2013-09, Vol.24 (9), p.2364-2370

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27, p.vi421-vi421

2016

Link zum Volltext

Verfügbarkeit prüfen

The allure of ‘ALUR’

Annals of oncology, 2018-06, Vol.29 (6), p.1344-1346

2018

Link zum Volltext

Verfügbarkeit prüfen

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001

Annals of oncology, 2019-04, Vol.30, p.ii48-ii49

2019

Link zum Volltext

Verfügbarkeit prüfen

Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology

Annals of oncology, 2007-01, Vol.18 (1), p.29-35

2007

Link zum Volltext

Verfügbarkeit prüfen

Reply to the letter to the editor ‘Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC’ by Ou et al

Annals of oncology, 2014-10, Vol.25 (10), p.2093-2093

2014

Link zum Volltext

Verfügbarkeit prüfen

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001

Annals of oncology, 2016-10, Vol.27, p.vi418-vi418

2016

Link zum Volltext

Verfügbarkeit prüfen

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27, p.vi437-vi437

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations

Annals of oncology, 2018-10, Vol.29, p.viii495-viii495

2018

Link zum Volltext

Verfügbarkeit prüfen

Kinase fusions in colorectal cancers: A unique biologic subset

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii152

2018

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types

Annals of oncology, 2017-11, Vol.28, p.x1-x1

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii503-viii504

2018

Link zum Volltext

Verfügbarkeit prüfen

Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor

Annals of oncology, 2016-10, Vol.27, p.vi493-vi493

2016

Link zum Volltext

Verfügbarkeit prüfen

Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP)

Annals of oncology, 2016-10, Vol.27, p.vi419-vi419

2016

Link zum Volltext

Verfügbarkeit prüfen

Rociletinib-associated cataracts in EGFR-mutant NSCLC

Annals of oncology, 2016-10, Vol.27, p.vi428-vi428

2016

Link zum Volltext

Verfügbarkeit prüfen

Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies

Annals of oncology, 2016-10, Vol.27, p.vi418-vi418

2016

Link zum Volltext

Verfügbarkeit prüfen

Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions

Annals of oncology, 2016-10, Vol.27, p.vi140-vi140

2016

Link zum Volltext

Verfügbarkeit prüfen

HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib

Annals of oncology, 2016-10, Vol.27, p.vi439-vi439

2016

Link zum Volltext

Verfügbarkeit prüfen

559P Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC

Annals of oncology, 2023-11, Vol.34, p.S1687-S1688

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(85)

Publikationsform

Artikel
(85)

Sprache

Englisch
(85)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Humans
(12)
Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Oncology
(11)
Crizotinib
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Female
(5)
Lung Neoplasms - Drug Therapy
(5)
Lung Neoplasms - Genetics
(5)
Mutation
(5)
Adult
(4)
Aged
(4)
Biological And Medical Sciences
(4)
Carcinoma, Non-Small-Cell Lung - Genetics
(4)
Male
(4)
Middle Aged
(4)
Anaplastic Lymphoma Kinase
(3)
Antineoplastic Agents
(3)
Lung Neoplasms - Pathology
(3)
Medical Sciences
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

Innovative personalized medicine in gastric cancer: time to move forward

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

The allure of ‘ALUR’

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001

Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology

Reply to the letter to the editor ‘Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC’ by Ou et al

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations

Kinase fusions in colorectal cancers: A unique biologic subset

Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types

Long-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)

Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor

Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP)

Rociletinib-associated cataracts in EGFR-mutant NSCLC

Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies

Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions

HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib

559P Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC

Suchergebnisse filtern